LDL CHOLESTEROL REDUCTION WITH BMS-962476, AN ADNECTIN INHIBITOR OF PCSK9: RESULTS OF A SINGLE ASCENDING DOSE STUDY

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

Evan A. Stein, Dan Gipe, Jean Bergeron et al. · The Lancet · 2012 · 575 citations

Metabolic Syndrome, Cardiovascular Disease, Stable Statin Dose +7

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga‐Morskaya et al. · The Lancet · 2013 · 571 citations · Full text

Metabolic Syndrome, Oxysterol, Biochemistry +9

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

James M. McKenney, Michael J. Koren, Dean J. Kereiakes et al. · Journal of the American College of Cardiology · 2012 · 504 citations

Thrombosis, Lipid Disorder, Cardiovascular Disease +9

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

Frederick J. Raal, Robert C. Scott, Ransi Somaratne et al. · Circulation · 2012 · 500 citations

Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients

David Sullivan, Anders Olsson, Robert C. Scott et al. · JAMA · 2012 · 445 citations